What question did this study set out to answer?

To assess how statin therapy alters platelet adhesion to fibrinogen and platelet aggregation stimulated by ADP, collagen, or ristocetin in individuals with type II hyperlipidemia.

January 1, 2013Archives of Medical ScienceOpen Access

Effect of statins on platelet function in patients with hyperlipidemia

View Full Paper

Ask AI

Bookmark

Why the study?

Does statin treatment reduce platelet aggregation and adhesion in patients with type II hyperlipidemia?

Population

70 persons: 50 patients with type II hyperlipidemia without concomitant diseases and 20 healthy volunteers…

Comparison

8-week statin treatment given once daily at… vs Healthy volunteers and baseline values before…

Design

Cohort, Laboratory assay was blinded to subject identity and study sequence.

Follow-up

8 weeks

Authors

JSJoanna SikoraMedical University of Lodz BKBarbara KostkaMedical University of Lodz IMIwona MarczykMedical University of Lodz

Discussion

Member takes

Implication

May reduce platelet aggregation in hyperlipidemia; observational data leave open clinical relevance and need for RCTs.

Key Points

To assess how statin therapy alters platelet adhesion to fibrinogen and platelet aggregation stimulated by ADP, collagen, or ristocetin in individuals with type II hyperlipidemia.
Assessed 70 participants consisting of 50 patients with type II hyperlipidemia without concomitant diseases and 20 healthy volunteers.
Administered 8 weeks of treatment with atorvastatin (10 mg/day), simvastatin (20 mg/day), or pravastatin (20 mg/day).
Measured spontaneous and ADP-activated platelet adhesion to fibrinogen, alongside platelet aggregation triggered by ADP, collagen, and ristocetin.
ADP-induced platelet aggregation decreased significantly across all treatment arms: atorvastatin from 50.6 ± 12.8% to 41.1 ± 15.8% (p < 0.05), simvastatin from 57.2 ± 18.0% to 44.7 ± 22.1% (p = 0.05), and pravastatin from 55.8 ± 19.5% to 38.8 ± 23.3% (p < 0.05).
Statins showed no significant effect on spontaneous or ADP-induced platelet adhesion to fibrinogen, nor on platelet aggregation induced by collagen or ristocetin.

Structured PICO

Does statin treatment reduce platelet aggregation and adhesion in patients with type II hyperlipidemia?

Population

70 persons: 50 patients with type II hyperlipidemia without concomitant diseases (mean age 58 ±8.2 years, 29 female) and 20 healthy volunteers (mean age 56 ±11.2 years, 9 female). Key inclusion: TC ≥250 mg/dl, LDL-C ≥170 mg/dl and TG ≤400 mg/dl.

Intervention

8-week statin treatment (atorvastatin 10 mg/day, simvastatin 20 mg/day, or pravastatin 20 mg/day) given once daily at bedtime.

Comparator

Healthy volunteers (n=20) and baseline values before treatment (no placebo group).

Outcome

Platelet adhesion to fibrinogen (spontaneous and ADP-activated) and ADP, collagen or ristocetin-induced aggregation.surrogate

Short-term statin therapy beneficially modifies ADP-induced platelet aggregation in patients with hyperlipidemia, independent of changes in platelet adhesion to fibrinogen.

Limitations

Small number of subjects
A placebo-treated group was not included

Cite This Study

Sikora et al. (2013) studied this question.

synapsesocial.com/papers/6a9435143fda5c29338c185d https://doi.org/10.5114/aoms.2013.36905

View Full Paper

Ask AI

Bookmark

Effect of statins on platelet function in patients with hyperlipidemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Effect of statins on platelet function in patients with hyperlipidemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider